SNY - China Approves AstraZeneca-Sanofi's Respiratory Syncytial Virus Drug To Prevent Infection In Infants | Benzinga
Tuesday, China's National Medical Products Administration approved AstraZeneca Plc (NASDAQ: AZN) and Sanofi SA's (NASDAQ: SNY) Beyfortus (nirsevimab), a long-acting monoclonal antibody for the prevention of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) in neonates and infants entering or during their first RSV season.
Beyfortus will be available during the 2024-2025 RSV season.
Beyfortus is the first approved preventive option to protect against RSV in a broad ...